| Brand Name | Skyrizi |
| Generic Name | Risankizumab |
| Drug Class | Anti-IL-23 Monoclonal Antibody |
| Availability | Prescription |
| Manufacturer | AbbVie |
| Indications | Ulcerative Colitis, Crohn's Disease |
| Type | Injection |
| Doses | 600 mg at weeks 0, 4, then every 8 weeks for maintenance. |
| Route | Subcutaneous |
| Side Effects | Headache, fatigue, injection site reactions, infections |
| Interactions | IL-23 inhibitor; increased infection risk; avoid live vaccines |
| Overdose | Headache, fatigue, infection risk. |
| Missed Dose | Take missed dose ASAP. |
| Contraindications | Serious infections, hypersensitivity to drug components. |
| Alternatives | Ustekinumab, Filgotinib |
| Co-Pay Assistance Program | Available Rx |
| Patient Assistance Program | Available |
Dr. Bharat Pothuri is a Board-Certified Gastroenterologist and Hepatologist. With extensive experience in digestive health, he specializes in advanced endoscopic procedures, chronic GI disorder management, and preventive care. Dr. Pothuri is dedicated to providing expert, patient-focused insights to help improve gut health and overall well-being.
Risankizumab is used to treat moderate to severe plaque psoriasis and is also being investigated for use in treating Crohn�s disease and ulcerative colitis.
Risankizumab works by targeting and inhibiting interleukin-23 (IL-23), a cytokine involved in the inflammatory response that contributes to skin cell overproduction in psoriasis.
Common side effects include upper respiratory infections, fatigue, and headache. Serious side effects may include infections or allergic reactions.
Risankizumab is administered as a subcutaneous injection, typically given every 12 weeks after an initial loading dose.
Yes, Risankizumab is being studied for other conditions, such as Crohn's disease and ulcerative colitis, due to its ability to target IL-23 and reduce inflammation.
If you miss a dose, take it as soon as you remember. If it�s nearly time for the next dose, skip the missed dose and resume your normal schedule. Contact your healthcare provider for further guidance.
Risankizumab should only be used during pregnancy if the potential benefits outweigh the risks. Consult your healthcare provider if you are pregnant or planning to become pregnant.
Risankizumab has shown strong effectiveness in clinical trials for reducing the severity of plaque psoriasis, with many patients experiencing significant skin improvement.
Yes, as an immunosuppressive medication, Risankizumab can increase the risk of infections. It is important to monitor for signs of infection and contact your doctor if any occur.
Risankizumab works by reducing inflammation in the intestines by targeting IL-23, which plays a role in the immune response in Crohn�s disease.
Related Conditions |
Related Blogs |
|---|---|
